What is the latest news on HIVNET 012?
The US National Institute of Health (NIH) conducted a clinical study in Uganda from 1997 to 1998 to examine the efficacy and safety of nevirapine for the prevention of Mother-to-Child-Transmission of HIV. The results of the study confirmed the efficacy and safety of nevirapine. The study is called HIVNET 012 and was published in a well-known scientific journal. Due to a recent discussion about documentation errors of the study Boehringer Ingelheim offers information material related to HIVNET 012 and nevirapine: • 23 December 2004 Letter of the Boehringer Ingelheim Corporate Medical Director to NGOs and interested AIDS specialists. Letter – PDF (99 KB) • December 2004 Medical background on HIVNET 012 and further clinical studies proving the efficacy and safety of nevirapine in the prevention of MTCT in developing countries.
